CoLucid Pharmaceuticals
Developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
Launch date
Employees
Market cap
-
Enterprise valuation
€873m (Public information from Jan 2017)
Durham North Carolina (HQ)
Authorizing premium user...